ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Daskivich on the Future Landscape of Prostate Cancer

Timothy J. Daskivich, MD
Published: Tuesday, Sep 18, 2018



Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses the future treatment landscape of prostate cancer.

Daskivich’s hope is that active surveillance will be the primary therapy for very low-risk and the majority of low-risk prostate cancers. For select low-risk prostate cancers, high-intensity focused ultrasound (HIFU) or other minimally invasive and minimally morbid treatments will be used for those patients who need treatment, states Daskivich. Currently, HIFU is only approved in the United States for prostate tissue ablation, but it has demonstrated efficacy as a treatment for patients with prostate cancer. HIFU should be used sparingly, as to avoid overtreatment in patients with very low-risk tumors.

For favorable-risk, low-volume, localized, intermediate-risk tumors, HIFU will become the standard of care, predicts Daskivich. For unfavorable, intermediate-risk and higher tumors, the evidence suggests that, currently, surgery and radiation are the appropriate therapies. Time will tell, concludes Daskivich.


Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses the future treatment landscape of prostate cancer.

Daskivich’s hope is that active surveillance will be the primary therapy for very low-risk and the majority of low-risk prostate cancers. For select low-risk prostate cancers, high-intensity focused ultrasound (HIFU) or other minimally invasive and minimally morbid treatments will be used for those patients who need treatment, states Daskivich. Currently, HIFU is only approved in the United States for prostate tissue ablation, but it has demonstrated efficacy as a treatment for patients with prostate cancer. HIFU should be used sparingly, as to avoid overtreatment in patients with very low-risk tumors.

For favorable-risk, low-volume, localized, intermediate-risk tumors, HIFU will become the standard of care, predicts Daskivich. For unfavorable, intermediate-risk and higher tumors, the evidence suggests that, currently, surgery and radiation are the appropriate therapies. Time will tell, concludes Daskivich.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x